|
|
Vaccine Detail
|
HUVECs-OK432 vaccine |
| Vaccine Information |
- Vaccine Name: HUVECs-OK432 vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007618
- Type: xenogeneic or syngeneic endothelial cells
- Status: Research
- Antigen: OK432
- Immunization Route: Intramuscular injection (i.m.)
- Description: Vaccination with xenogeneic or syngeneic endothelial cells targeting tumor angiogenesis is effective for inhibiting tumor growth. OK432, an effective adjuvant, was mixed with viable human umbilical vein endothelial cells (HUVECs) to prepare a novel HUVECs-OK432 vaccine, which could have an improved therapeutic efficacy (Xu et al., 2013).
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: a stronger HUVEC-specific Abs and cytotoxic T lymphocyte immune response were elicited (Xu et al., 2013).
|
| References |
Xu et al., 2013: Xu M, Xing Y, Zhou L, Yang X, Yao W, Xiao W, Ge C, Ma Y, Yang J, Wu J, Cao R, Li T, Liu J. Improved efficacy of therapeutic vaccination with viable human umbilical vein endothelial cells against murine melanoma by introduction of OK432 as adjuvant. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34(3); 1399-1408. [PubMed: 23456765].
|
|
